OWLT — what changed in the latest 10-Q
A section-by-section comparison of OWLT's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-08-14 vs the prior 10-Q · 2026-05-11
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +39 | −29 | ~13 | 13 |
| Market risk (Item 3) | No paragraph-level changes | 0 | 0 | 0 | 1 |
| Controls & procedures | Text added/removed | +8 | −2 | ~4 | 10 |
| Legal proceedings | Text added/removed | +2 | 0 | ~1 | 0 |
| Risk factors | No material changes reported (points to the 10-K) | — | — | — | — |
| Other information | Text added/removed | +2 | −3 | 0 | 0 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-08-14
Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance, and testing of our products, platforms and services, including quality and clinica…
In addition, from time to time, our operating expenses include restructuring costs. Restructuring costs in the periods presented primarily related to employee severance in connection with our CEO transition in April 2026 and, to a lesser extent, management-approved plans designed to improve our cost…
Loss on debt extinguishment. Excess of the reacquisition price paid to settle debt over its net carrying value.
Allocation of accretion on convertible preferred stock to redeemable common stock7 29 18 59
Allocation of net loss attributable to redeemable common stockholders5 1,293 42 1,183
Text removed vs the prior filing · source: 10-Q · 2026-05-11
Research and Development. Research and development expenses consist primarily of salaries, benefits, stock-based compensation, and bonuses for employees and contractors engaged in the design, development, maintenance, and testing of our products, platforms and services, including quality and clinica…
Net income (loss) and comprehensive income (loss)$(3,336)$3,025
Allocation of accretion on convertible preferred stock to redeemable common stock11 —
Allocation of net income to participating securities to redeemable common stockholders— 14
Net income (loss) attributable to redeemable common stockholders(42)86
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-08-14
Remediation of Previously Reported Material Weaknesses in Internal Control Over Financial Reporting
As previously reported in our Form 10-Q for the period ending March 31, 2026, we identified material weaknesses in our internal control over financial reporting. The material weaknesses previously identified included the following:
•We did not design and maintain effective controls over the accounting for debt and equity arrangements, including convertible preferred stock, warrant arrangements, and stock-based compensation modifications.
•We did not design and maintain effective controls over IT general controls for information systems that are relevant to the preparation of our consolidated financial statements. Specifically, we did not design and maintain (i) program change management controls to ensure that IT program and data ch…
In response to these identified material weaknesses, our management, with the oversight of the Audit Committee of our board of directors, has been actively engaged in remediating the above material weaknesses. During the year ended December 31, 2025, we implemented remediation measures designed to r…
Text removed vs the prior filing · source: 10-Q · 2026-05-11
•We did not design and maintain effective controls over the accounting for debt and equity arrangements, including convertible preferred stock, warrant arrangements, and stock-based compensation modifications. Each of these material weaknesses resulted in material adjustments to several account bala…
•We did not design and maintain effective controls over IT general controls for information systems that are relevant to the preparation of our consolidated financial statements. Specifically, we did not design and maintain (i) program change management controls to ensure that IT program and data ch…
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-08-14
On August 3, 2026, the U.S. District Court for the Central District of California entered final orders granting final approval of the settlements in both the consolidated securities class action (Butala v. Owlet, Inc., Case No. 2:21-cv-09016-FLA-SSC) and the consolidated shareholder derivative actio…
For a detailed description of these finalized settlements and our general legal proceedings, see Note 5, Commitments and Contingencies, within the Notes to Condensed Consolidated Financial Statements included elsewhere in this Report, which is incorporated herein by reference.
Other information
Text added vs the prior filing · source: 10-Q · 2026-08-14
(c) On June 15, 2026, Amanda Twede Crawford, Chief Financial Officer of the Company, entered into a Rule 10b5-1 trading arrangement (the "10b5-1 Plan"). Ms. Crawford's 10b5-1 Plan provides for the potential sale of up to 162,288 shares of the Company's common stock. The plan commences on September 1…
During the three months ended June 30, 2026, none of the Company's other directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated “Rule 10b5-1 trading arrangements” and/or “non-Rule 10b5-1 trading arrangements,” each as defined in It…
Text removed vs the prior filing · source: 10-Q · 2026-05-11
Our Board of Directors has set the date of the Company’s 2026 Annual Meeting of Stockholders (the “2026 Annual Meeting”) for July 10, 2026. The exact time and place of the 2026 Annual Meeting will be specified in our Notice of 2026 Annual Meeting and related proxy statement for the 2026 Annual Meeti…
Because the date of the 2026 Annual Meeting has been changed by more than 30 days from the first anniversary of our 2025 Annual Meeting of Stockholders, the Board has set a new deadline for the receipt of any stockholder proposals submitted for the 2026 Annual Meeting. If a stockholder desires to pr…
(c) During the three months ended March 31, 2026, no directors or “officers” (as defined in Rule 16a-1(f) under the Exchange Act) of the Company adopted, modified or terminated “Rule 10b5-1 trading arrangements” and/or “non-Rule 10b5-1 trading arrangements,” each as defined in Item 408 of Regulation…
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice